Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Steven Nissen, MD

216.444.6697

Steven Nissen, MD
Department: Cardiovascular Medicine
Department Chair
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6855
Steven Nissen, MD
Department: Molecular Cardiology
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6855
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Steven Nissen, MD, is the Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute. He was appointed to this position in 2006 after serving nine years as Vice Chairman of the Department of Cardiology and five years as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multicenter clinical trials.

Dr. Nissen’s research during the last two decades has focused on the application of intravascular ultrasound (IVUS) imaging to study the progression and regression of coronary atherosclerosis. He has served as International Principal Investigator for several large IVUS multicenter atherosclerosis trials.

Specialty/Clinical interests: General cardiology, intravascular ultrasound (IVUS), diabetes and the heart, drug safety, coronary intensive care

Experience: Dr. Nissen has more than 35 years of experience as a physician. He is world-renowned for his work as a cardiologist, patient advocate and researcher. Equally as significant is his pioneering work in IVUS technology and its use in patients with atherosclerosis.

Publications and Speaking: Dr. Nissen has written more than 350 journal articles and 60 book chapters, including many published in the New England Journal of Medicine and the Journal of the American Medical Association. In recent years, he has also written on the subject of drug safety and was the author of manuscripts highlighting concerns about medications such as Vioxx™, Avandia™, and muraglitazar.
He has testified in both the Senate and the House of Representatives on the topic of drug safety as well as the need to reform the Food and Drug Administration (FDA).

As a physician/scientist, Dr. Nissen is often called on by pharmaceutical companies to consult on the development of new therapies for cardiovascular disease. He maintains a long-standing personal policy that requires these companies to donate all related honoraria directly to charity.

Dr. Nissen is currently the editor of Current Cardiology Report.  In 2007, he was listed as Time Magazine’s “100 Most Influential People in the World – Scientists and Thinkers."

He is heavily involved with the American College of Cardiology (ACC), serving as President from March 2006 to March 2007, a member of the ACC Executive Committee from 2004 to 2008, and spending 10 years as a member of the organization’s Board of Trustees. In addition, Dr. Nissen has served several terms on the Program Committee for the ACC Annual Scientific Sessions.

Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for five years, and as chair of the final year of his membership. He continues to serve as a periodic advisor to several FDA committees as a Special Government Employee.

Dr. Nissen frequently lectures at national and international meetings. He has served as visiting professor, or provided Grand Rounds, at nearly 100 institutions.
 
About Dr. Nissen:
“I am fiercely independent and don't accept compensation from industry for consulting or speaking.”

Leisure time activities: In his leisure time, Dr. Nissen likes to bicycle whenever possible. He is also an advanced amateur photographer.

Professional Highlights

  • Principal Investigator, Global Cardiovascular Innovation Center, Cleveland Clinic, 2006
  • Director, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic
  • Member, National Institutes of Health Level 1 Working Group on Clinical Trial Design National Heart, Lung, and Blood Institute (NHLBI), 2006
  • National Government Service: Presently serves as Special Government Employee as periodic advisor to the U.S. Food and Drug Administration (FDA).
  • Chairman, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, FDA, 2004 - 2005
  • Member, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, FDA, 2000 - 2004
  • Medical Director, Cleveland Clinic Cardiovascular Coordinating Center - an organization that directs multicenter clinical trials, 2001 - 2006

Education & Fellowships

Fellowship - University of Kentucky Chandler Medical Center
Cardiology
Lexington, KY USA
1983
Residency - University of California Davis Medical Center
Internal Medicine
Sacramento, CA USA
1981
Internship - University of California Davis Medical Center
Medical Internship
Sacramento, CA USA
1979
Medical School - University of Michigan Medical School
Ann Arbor, MI USA
1978
Undergraduate - University of Michigan
Ann Arbor, MI USA
1974

Certifications

  • Internal Medicine
  • Internal Medicine- Cardiovascular Disease

Specialty Interests

General cardiology, heart disease, intravascular ultrasound, digital angiography and computer image processing, coronary intensive care

Awards & Honors

  • Best Doctors, Cleveland Magazine, 2008, 2014
  • America’s Top Doctors, Castle Connolly, 2014
  • Golden Achievement for Medicine Award, Golden Age Centers of Greater Cleveland, 2012
  • Simon Dack Award for Outstanding Scholarship, Awarded by Journal of American College of Cardiology Editorial Board and the American College of Cardiology, 2011
  • Most Interesting People, Cleveland Magazine, 2010
  • "100 Most Influential People in the World – Scientists and Thinkers," TIME Magazine, 2007
    "Country’s 30 Most Powerful Forces in Business and Finance," Smart Money, 2007
  • President, American College of Cardiology, a 34,000-member, non-profit, professional medical society whose mission is to advocate for quality cardiovascular care - through education, research promotion, development and application of standards and guidelines - and to influence health care policy, March 2006 thru March 2007
  • Honorary Member of the Japanese College of Cardiology (JCC), 2007
  • Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky, 2004
  • Outstanding Scientist Award, Cleveland Clinic, 2004
  • Three-time recipient of the Outstanding Teacher Award, Fellows of Cardiovascular Medicine at Cleveland Clinic (2004, 1998, 1994)
  • Dr. Nissen has received a number of additional honors and recognitions

Additional Training

  • Intensive Care Units Committee, University of Kentucky Medical Center, 1983-1992
  • Aeromedical Patient Care for the University of Kentucky, 1987-1992
  • Certification - Cardiovascular Medicine, American Board of Internal Medicine, 1983
  • Certification - American Board of Internal Medicine, 1979
  • Certification - National Board of Medical Examiners, 1979

Innovations & Patents

  • Intravascular ultrasound (IVUS) and application to patients with atherosclerosis. Dr. Nissen has served as principal investigator for 6 major trials using IVUS to assess coronary disease and is currently conducting several additional atherosclerosis studies.
  • Co-chairman, American College of Cardiology and the European Society of Cardiology International Writing Group to develop an Expert Consensus Document on Standards for the Acquisition, Measurement, and Reporting of Intravascular Ultrasound Studies, 1999-2001.
  • Member, National Joint Committee of the American College of Cardiology and the American Heart Association to revise 1990 Coronary Angiography Guidelines, 1995-2000.
  • Appointed committee member in the development of CD-ROM Version of the American College of Cardiology Self-Assessment Program (ACC-SAP), 1994-1996.
  • Co-chairman, Joint Committees of the American College of Cardiology and National Electronics Manufacturers Association for Digital Imaging and Communication for Medicine (DICOM) Working Group I, Task Force to Develop Standards for Digital Image Archiving Devices for Cardiac Catheterization Laboratories, 1992-2000.

Memberships

  • American College of Cardiology
  • Association of Professors of Cardiology
  • American University of Physicians
  • AHA Council on Cardiovascular Radiology (Elected Fellow 1991)
  • AHA Council on Clinical Cardiology

Recent National Committees and Positions

  • 2013 Harvard Multi-Regional Clinical Trial Center Working Group, Harvard University and Global Institute of Health, Cambridge, ME
  • 2013 Writing Committee Cardiovascular Endpoints in Clinical Trials, American College of Cardiology
  • 2010 - Present, Standardized Data Collection for Cardiovascular Trials, FDA
  • 2010 Steering Committee Member, Clinical Trials Transformation Initiative (CTTI), Translational Institute, Duke University
  • 2010 – Present, Editorial Board Seat, Prescribers Letter, Therapeutic Research Center
  • 2010 Advisor, Prevention Magazine, Rodale Publishing
  • 2002 – 2014 Senior Consulting Editor to the Journal of the American College of Cardiology. 

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/1/2014, Dr. Nissen has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Charity. Dr. Nissen has consulted for the following companies but instructed them to donate all compensation directly to one or more non-profit organizations:

  • Novo Nordisk, A/S

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English